S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:ACHV

Achieve Life Sciences (ACHV) Stock Forecast, Price & News

$6.79
+0.15 (+2.26%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
$6.60
$6.91
50-Day Range
$6.30
$7.98
52-Week Range
$5.62
$10.40
Volume
26,837 shs
Average Volume
74,164 shs
Market Capitalization
$64.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.13
30 days | 90 days | 365 days | Advanced Chart
Receive ACHV News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Achieve Life Sciences logo

About Achieve Life Sciences

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACHV
CUSIP
68230A10
Employees
16
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.97 per share

Profitability

Net Income
$-33.15 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
9,575,000
Market Cap
$64.34 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/16/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

849th out of 1,423 stocks

Diagnostic Substances Industry

12th out of 27 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Achieve Life Sciences (NASDAQ:ACHV) Frequently Asked Questions

Is Achieve Life Sciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Achieve Life Sciences stock.
View analyst ratings for Achieve Life Sciences
or view top-rated stocks.

Are investors shorting Achieve Life Sciences?

Achieve Life Sciences saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 426,700 shares, an increase of 36.7% from the April 15th total of 312,200 shares. Based on an average trading volume of 84,900 shares, the days-to-cover ratio is currently 5.0 days.
View Achieve Life Sciences' Short Interest
.

When is Achieve Life Sciences' next earnings date?

Achieve Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Achieve Life Sciences
.

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted its quarterly earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.09. During the same quarter in the prior year, the business earned ($1.30) earnings per share.
View Achieve Life Sciences' earnings history
.

When did Achieve Life Sciences' stock split? How did Achieve Life Sciences' stock split work?

Achieve Life Sciences shares reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for ACHV?

4 brokers have issued 12-month price targets for Achieve Life Sciences' shares. Their forecasts range from $21.00 to $27.00. On average, they anticipate Achieve Life Sciences' stock price to reach $24.25 in the next twelve months. This suggests a possible upside of 257.1% from the stock's current price.
View analysts' price targets for Achieve Life Sciences
or view top-rated stocks among Wall Street analysts.

Who are Achieve Life Sciences' key executives?
Achieve Life Sciences' management team includes the following people:
  • Dr. Richard A. B. Stewart, Exec. Chairman (Age 63, Pay $699.48k)
  • Mr. John A. Bencich, CEO & Director (Age 45, Pay $620.52k) (LinkedIn Profile)
  • Dr. Cindy Jacobs M.D., Ph.D., Pres, Chief Medical Officer & Director (Age 64, Pay $579.81k)
  • Mr. Jerry Wan, Principal Accounting Officer (Age 40)
  • Dr. Anthony Clarke, Chief Scientific Officer (Age 66)
  • Ms. Jaime Xinos, Exec. VP of Commercial
What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).

What is Achieve Life Sciences' stock symbol?

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.62%), DLD Asset Management LP (0.48%), Oppenheimer & Co. Inc. (0.24%), State Street Corp (0.20%), Raymond James & Associates (0.14%) and Charles Schwab Investment Management Inc. (0.11%).
View institutional ownership trends for Achieve Life Sciences
.

Which institutional investors are selling Achieve Life Sciences stock?

ACHV stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Oppenheimer & Co. Inc., and Simplex Trading LLC.
View insider buying and selling activity for Achieve Life Sciences
or view top insider-selling stocks.

Which institutional investors are buying Achieve Life Sciences stock?

ACHV stock was purchased by a variety of institutional investors in the last quarter, including DLD Asset Management LP, Raymond James & Associates, Charles Schwab Investment Management Inc., State Street Corp, and Cutler Group LP.
View insider buying and selling activity for Achieve Life Sciences
or or view top insider-buying stocks.

How do I buy shares of Achieve Life Sciences?

Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Achieve Life Sciences' stock price today?

One share of ACHV stock can currently be purchased for approximately $6.79.

How much money does Achieve Life Sciences make?

Achieve Life Sciences has a market capitalization of $64.34 million. The biopharmaceutical company earns $-33.15 million in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Achieve Life Sciences have?

Achieve Life Sciences employs 16 workers across the globe.

What is Achieve Life Sciences' official website?

The official website for Achieve Life Sciences is achievelifesciences.com.

How can I contact Achieve Life Sciences?

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at [email protected], or via fax at 425-686-1600.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.